公开(公告)号：US11484534B2

公开(公告)日：2022-11-01

申请号：US15431906

申请日：2017-02-14

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： A61K31/498 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160317603A9

公开(公告)日：2016-11-03

申请号：US14676378

申请日：2015-04-01

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

CPC分类号： A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20150283199A1

公开(公告)日：2015-10-08

申请号：US14676378

申请日：2015-04-01

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

CPC分类号： A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

摘要翻译： 本发明具有用于治疗HCV的无干扰素治疗。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 一方面，治疗包括给具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林，其中所述治疗持续12周，并且不包括施用干扰素，并且所述至少两种直接作用的抗病毒剂包含 a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

公开(公告)号：US20150164976A1

公开(公告)日：2015-06-18

申请号：US14628849

申请日：2015-02-23

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Scott C. Brun ,  Daniel E. Cohen ,  Emily O. Dumas ,  Sandeep Dutta ,  Amit Khatri ,  Cheri E. Klein ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki

IPC分类号： A61K38/07 ,  A61K31/427 ,  A61K31/7056 ,  A61K31/513 ,  A61K38/05

CPC分类号： A61K38/07 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/12 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

公开(公告)号：US20140107017A1

公开(公告)日：2014-04-17

申请号：US14138515

申请日：2013-12-23

申请人： AbbVie Inc.

发明人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein ,  Thomas J. Podsadecki

IPC分类号： A61K38/12 ,  A61K31/427 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/513 ,  A61K31/4025

CPC分类号： A61K38/07 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/12 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

摘要翻译： 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗过程持续时间较短，例如不超过12周。 在一个方面，治疗方法包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3），细胞色素P450抑制剂（例如利托那韦）和利巴韦林。

公开(公告)号：US20140107016A1

公开(公告)日：2014-04-17

申请号：US14138449

申请日：2013-12-23

申请人： AbbVie Inc.

发明人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein ,  Thomas J. Podsadecki

IPC分类号： A61K38/12 ,  A61K31/427 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/4025 ,  A61K31/513

CPC分类号： A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G06F19/12

摘要： The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US20240232171A1

公开(公告)日：2024-07-11

申请号：US18613308

申请日：2024-03-22

申请人： ABBVIE INC.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： G06F16/23 ,  G06F7/00 ,  G06F16/215 ,  G06F16/25

CPC分类号： G06F16/2365 ,  G06F7/00 ,  G06F16/215 ,  G06F16/2379 ,  G06F16/252

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180177779A1

公开(公告)日：2018-06-28

申请号：US15738773

申请日：2016-07-07

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： A61K31/498 ,  A61K31/454 ,  A61K31/7072 ,  A61P31/14

CPC分类号： A61K31/498 ,  A61K31/454 ,  A61K31/7056 ,  A61K31/7072 ,  A61P31/14 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180042982A1

公开(公告)日：2018-02-15

申请号：US15782162

申请日：2017-10-12

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Tami Pilot-Matias ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Lino Rodrigues Junior ,  Suvajit Samanti ,  Roger Trinh ,  Tianli Wang ,  Betty B. Yao

IPC分类号： A61K38/06 ,  A61K31/7072 ,  A61K31/4184 ,  A61K31/7056

CPC分类号： A61K38/06 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

摘要： The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.

公开(公告)号：US20170151238A1

公开(公告)日：2017-06-01

申请号：US15431906

申请日：2017-02-14

申请人： AbbVie Inc.

发明人： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC分类号： A61K31/498 ,  A61K31/454

CPC分类号： A61K31/498 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.